| Literature DB >> 26516006 |
Jean-Michel Paradis1, Maria Del Trigo1, Rishi Puri1, Josep Rodés-Cabau2.
Abstract
Bioprosthetic valve use has increased significantly. Considering their limited durability, there will remain an ongoing clinical need for repairing or replacing these prostheses in the future. The current standard of care for treating bioprosthetic valve degeneration involves redo open-heart surgery. However, repeat cardiac surgery may be associated with significant morbidity and mortality. With the rapid evolution of transcatheter heart valve therapies, the feasibility and safety of implanting a transcatheter heart valve within a failed tissue valve has been established. We review the historical perspective of transcatheter valve-in-valve therapy, as well as the main procedural challenges and clinical outcomes associated with this new less invasive treatment option.Entities:
Keywords: bioprosthetic dysfunction; transcatheter aortic valve replacement; valve failure
Mesh:
Year: 2015 PMID: 26516006 DOI: 10.1016/j.jacc.2015.09.015
Source DB: PubMed Journal: J Am Coll Cardiol ISSN: 0735-1097 Impact factor: 24.094